IP Library Granted Patent US 10,640,776
Granted Patent B2
US 10,640,776 · App. 15/698,259 · Granted May 5, 2020

Method for propagating adenoviral vectors encoding inhibitory gene products

Inventors: Jason G. D. Gall (Germantown, MD); Douglas E. Brough (Gaithersburg, MD); C. Richter King (New York, NY)
Assignee: GenVec, Inc.
C12N15/635C12N7/00C12N15/86C12N2710/10343C12N2710/10352C12N2830/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,776
App. No.
15/698,259
Granted
May 5, 2020
Kind
B2
Abstract

The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.

Claims (10)

1. A method of propagating a non-subgroup C adenoviral vector, which method comprises:

(a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR),

(b) expressing the nucleic acid sequence encoding tetR to produce tetR, and

(c) contacting the cell with a non-subgroup C adenoviral vector in the absence of tetracycline, wherein the non-subgroup C adenoviral vector has an adenoviral genome comprising a heterologous nucleic acid sequence, wherein the heterologous nucleic acid sequence (i) encodes a protein that inhibits propagation of the adenoviral vector in the cell and (ii) is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), so as to transduce the cell with the non-subgroup C adenoviral vector, wherein expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, and a non-subgroup C adenoviral vector is propagated,

wherein the non-subgroup C adenoviral vector is replication-deficient,

wherein the non-subgroup C adenoviral vector requires, at most, complementation of the E4 region of the adenoviral genome for replication, and

wherein the heterologous nucleic acid sequence encodes a viral protein from family Coronaviridae or Picornaviridae.

2. The method of claim 1 , wherein the heterologous nucleic acid sequence encodes a poliovirus protein, an apthovirus protein, or a foot-and-mouth disease viral protein.

3. The method of claim 1 , wherein the heterologous nucleic acid sequence encodes a viral protein from family Coronaviridae or Picornaviridae.

4. The method of claim 3 , wherein the heterologous nucleic acid sequence encodes a poliovirus protein, an apthovirus protein, or a foot-and-mouth disease viral protein.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →